Understanding heart risks from cancer immunotherapy
Risk Assessment and Outcomes Across the Clinical Spectrum of Cardiotoxicity from Immune Checkpoint Inhibitors
This study is looking at how cancer treatments called immune checkpoint inhibitors might affect the heart, especially in patients with certain heart markers, to help figure out who can safely keep using these treatments even if they have heart symptoms.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-10996621 on NIH RePORTER |
What this research studies
This research investigates the heart-related side effects of immune checkpoint inhibitors (ICIs), which are treatments for cancer. It aims to identify how different patients experience cardiotoxicity, particularly focusing on those with abnormal troponin-I levels. By analyzing both past and current patient data, the study seeks to determine which patients can safely continue their cancer treatment despite experiencing heart-related symptoms. The goal is to improve patient safety and treatment outcomes by better understanding the risks associated with these therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients receiving immune checkpoint inhibitors who may be experiencing or at risk for heart-related side effects.
Not a fit: Patients who are not undergoing treatment with immune checkpoint inhibitors or those without any cardiovascular concerns may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer cancer treatment options for patients experiencing heart-related side effects from immunotherapy.
How similar studies have performed: Previous research has shown promising results in monitoring and managing cardiotoxicity in cancer patients, indicating that this approach has potential for success.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Cheng, Evaline — Stanford University
- Study coordinator: Cheng, Evaline
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.